Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants - Top-Institutions - MDSpire

Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants

  • By

  • Ching-Hsuan Hsu

  • Ting-Yi Chang

  • Ya-Min Chang

  • Shin-Han Lin

  • Tzu-Ning Chen

  • Keng-Hao Hsu

  • Jhong-Jhe You

  • June 17, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Stanford University School of Medicine/Stanford Health Care
    Stanford University School of Medicine/Stanford Health Care

    Stanford, California

    Key Differentiators

    • Immunology

  • #2

    The Rockefeller University
    The Rockefeller University

    New York, New York

    Key Differentiators

    • Immunology

  • #3

    University Hospital Regensburg
    University Hospital Regensburg

    Regensburg, Bavaria

    Key Differentiators

    • Immunology

  • #4

    University of Regensburg
    University of Regensburg

    Regensburg, Bavaria

    Key Differentiators

    • Immunology

  • #5

    Technical University of Munich
    Technical University of Munich

    Munich, Bavaria

    Key Differentiators

    • Immunology

Original Source(s)

Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants

  • by Ching-Hsuan Hsu, Ting-Yi Chang, Ya-Min Chang, Shin-Han Lin, Tzu-Ning Chen, Keng-Hao Hsu, Jhong-Jhe You

  • June 17, 2026

Related Content

Predictive biomarkers of COVID-19 impact in renal transplant patients: an exploratory proteomic and cytokine analysis

The stand-alone Ayurveda treatment for the management of COVID-associated mucormycosis (CAM): a case report

Acute pancreatitis temporally associated with COVID-19 pneumonia in a patient with post-tuberculosis chronic pulmonary aspergillosis: a case report